- Home
- GANX vs COEP Comparison
GANX vs COEP Comparison
Compare GANX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- COEP
- Stock Information
- Founded
- GANX 2017
- COEP 2017
- Country
- GANX United States
- COEP United States
- Employees
- GANX N/A
- COEP N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GANX Health Care
- COEP Health Care
- Exchange
- GANX Nasdaq
- COEP Nasdaq
- Market Cap
- GANX 69.0M
- COEP 62.4M
- IPO Year
- GANX 2021
- COEP N/A
- Fundamental
- Price
- GANX $1.64
- COEP $12.79
- Analyst Decision
- GANX Strong Buy
- COEP
- Analyst Count
- GANX 5
- COEP 0
- Target Price
- GANX $8.20
- COEP N/A
- AVG Volume (30 Days)
- GANX 614.4K
- COEP 39.8K
- Earning Date
- GANX 11-13-2025
- COEP 11-12-2025
- Dividend Yield
- GANX N/A
- COEP N/A
- EPS Growth
- GANX N/A
- COEP N/A
- EPS
- GANX N/A
- COEP N/A
- Revenue
- GANX N/A
- COEP $263,555.00
- Revenue This Year
- GANX N/A
- COEP N/A
- Revenue Next Year
- GANX N/A
- COEP N/A
- P/E Ratio
- GANX N/A
- COEP N/A
- Revenue Growth
- GANX N/A
- COEP N/A
- 52 Week Low
- GANX $1.36
- COEP $2.31
- 52 Week High
- GANX $3.19
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- GANX 43.33
- COEP 53.18
- Support Level
- GANX $1.55
- COEP $12.09
- Resistance Level
- GANX $1.78
- COEP $13.53
- Average True Range (ATR)
- GANX 0.13
- COEP 0.74
- MACD
- GANX -0.03
- COEP -0.12
- Stochastic Oscillator
- GANX 18.00
- COEP 51.53
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.